查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1809668

女性不孕症診斷與治療市場（治療方法、診斷技術、不孕症類型與通路）－2025-2030 年全球預測

Female Infertility Diagnosis & Treatment Market by Treatment Method, Diagnosis Technique, Type of Infertility, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年女性不孕症診斷和治療市場價值為 49 億美元，預計 2025 年將成長至 52.9 億美元，複合年成長率為 8.14%，預計到 2030 年將達到 78.5 億美元。

主要市場統計數據
基準年2024年 49億美元
預計2025年 52.9億美元
預測年份 2030 78.5億美元
複合年成長率（%） 8.14%

女性不孕症診斷和治療領域的新興動態凸顯了整個醫療生態系統相關人員面臨的重大挑戰和機會

在患者期望不斷變化和技術突破的推動下，女性不孕症的診斷和治療已成為生殖醫學領域的關鍵關注領域。過去十年，隨著人們對不孕症問題的認知不斷提高，加之人口結構向晚育轉變，對精密診斷工具和個人化治療方法的需求空前高漲。因此，醫療保健提供者和產品開發者被迫改進臨床通訊協定，並引入創新解決方案，以提高成功率，同時最大限度地減輕患者負擔。

關鍵技術和臨床變化將重新定義女性不孕症的診斷和治療前景，改善患者的治療結果和治療途徑

診斷和治療技術的快速創新正在從根本上改變女性不孕症的格局，掀起一股變革浪潮，有望提高療效並改善患者體驗。新的生物標記組合和次世代定序提高了基因檢測的準確性，使醫生能夠更自信地識別染色體異常和遺傳風險因素。這些基因洞察如今正為制定標靶治療方案提供訊息，從而最佳化刺激方案和胚胎選擇標準。

評估美國關稅調整對女性不孕症診斷和治療供應鏈和成本結構的廣泛影響

美國對進口醫療設備、檢測試劑和藥物化合物徵收的新關稅於2025年初生效，給支持女性不孕症治療的供應鏈帶來了新的挑戰。設備製造商面臨超音波探頭和孵化器的投入成本增加，而診斷劑供應商則面臨基因檢測套組關稅增加。因此，診所和實驗室必須重新評估籌資策略，以維持病患的價格穩定。

深入研究治療方法、診斷技術、不孕症類型和銷售管道，揭示市場區隔的動態

深入了解市場細分可以揭示女性不孕症服務成長和差異化的關鍵途徑。治療方法可分為輔助生殖技術、冷凍保存、不孕症藥物和外科手術介入。輔助生殖技術包括輸卵管內配子移植、體外受精、卵細胞質內單一精蟲顯微注射術及子宮內授精等技術。在冷凍保存領域，胚胎、卵子和精子儲存的進步正在推動患者對不孕症治療方案的需求。生育藥物包括克羅米芬檸檬酸鹽、促性腺激素分泌和來曲唑，每種藥物都有不同的風險效益特徵。外科手術介入包括子宮鏡、腹腔鏡檢查、肌瘤切除術和輸卵管手術，每種手術都針對特定的解剖或病理狀況量身定做。

評估美洲、中東/非洲和亞太地區女性不孕症診斷和治療趨勢的區域差異

區域動態在影響女性不孕症診斷和治療方法的可及性、報銷和採用率方面發揮關鍵作用。在美洲，不斷擴大的私人醫療網路和輔助生殖技術保險覆蓋範圍的擴大，正在推動診所的擴張和患者數量的增加。北美的法律規範不斷發展，一些州允許生殖旅遊和跨境治療擁有更大的自主權，而拉丁美洲市場則正在利用具有成本效益的服務模式來吸引國際患者。

介紹產業領導者及其推動女性不孕症診斷和治療解決方案創新的策略性舉措

女性不孕症領域的主要企業正在利用策略夥伴關係、研發投入和地理擴張等多種手段來鞏固其市場地位。診斷創新者正在與學術機構合作，檢驗生物標記的發現；而設備製造商則正在推出合資企業，共同開發整合式試管嬰兒實驗室主機。製藥公司正在加強其下一代生育治療的後期臨床研發管線，旨在降低週期取消率，並最大程度地減少卵巢刺激相關的副作用。

產業領導者增強競爭力、推動女性不孕症護理永續發展的策略挑戰和實際步驟

尋求保持競爭力的行業領導者必須採取多管齊下的策略，在技術創新與以患者為中心的護理模式之間取得平衡。首先，將內部研發重點與新興臨床需求（例如非侵入性胚胎診斷和單細胞基因檢測）結合，可以釋放新的價值提案。同時，投資模組化實踐架構和數位健康平台，可以實現跨地域的可擴展服務交付。

詳細描述女性生育治療創新研究框架的資料來源和分析方法

本研究採用綜合研究框架，將一手資料、二手資料和專家檢驗結合，以提供可靠且可操作的見解。一手資料研究包括與生殖專家、實驗室主任和供應鏈經理進行結構化討論，以獲得關於技術應用和營運挑戰的第一手觀點。二手資料來源包括同儕審查日誌、監管備案文件和臨床試驗註冊中心，以整理新興趨勢與既定證據。

影響女性不孕症診斷和治療性介入未來的關鍵發現和策略觀點的摘要

本執行摘要概述了影響女性不孕症診斷和治療的關鍵促進因素、新興技術和策略考慮。從先進的基因檢測方法和人工智慧成像平台，到新資費政策對營運的影響，該領域正在迅速演變。透過對治療方式、診斷技術、不孕症類型和分銷管道的細分，我們可以多角度地了解市場的複雜性和患者需求。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章市場動態

  • 將人工智慧演算法融入個人化生育治療計劃
  • 擴大採用遠端醫療平台進行虛擬生育諮詢和遠端監控
  • 擴展家庭荷爾蒙監測解決方案，以便早期發現排卵障礙
  • 非侵入性子宮內膜容受性檢測的進展提高了胚胎移植的成功率
  • 擴大使用微流體精子分選技術來提高體外受精週期中的受精成功率
  • 將腸道微生物分析整合到生育能力評估中，以製定個人化治療決策
  • 支持擴大非處方不孕症診斷試劑套件和服務的監管變化
  • 新興的個人化卵巢組織冷凍保存通訊協定可改善生育力保存結果
  • 以患者為中心的數位支援工具在減輕不孕症治療期間的精神壓力方面的重要性日益凸顯
  • 以患者為中心的數位支援平台在生育治療期間提供情感護理工具和社區參與。

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章 2025年美國關稅的累積影響

第 8 章：女性不孕症診斷與治療市場（依治療方法）

  • 輔助生殖技術
    • 配子輸卵管植入
    • 體外受精
    • 卵細胞質內單一精蟲顯微注射術
    • 子宮內人工授精
  • 冷凍保存
    • 胚胎冷凍保存
    • 卵子冷凍保存
    • 精子冷凍保存
  • 生育藥物
    • 克羅米芬檸檬酸鹽
    • 促性腺激素分泌
    • 來曲唑
  • 外科手術干預
    • 子宮鏡手術
    • 腹腔鏡手術
    • 子宮肌瘤切除術
    • 輸卵管手術

9. 女性不孕症診斷與治療市場（依診斷技術）

  • 血液學診斷
    • 抗穆氏管荷爾蒙檢測
    • 濾泡刺激素檢測
    • 黃體激素檢測
    • 催乳素測試
  • 基因檢測
  • 造影
  • 腹腔鏡檢查
  • 超音波影像

第 10 章：女性不孕症診斷與治療市場（依不孕症類型）

  • 原發性不孕症
  • 續發性不孕症

第 11 章：女性不孕症診斷與治療市場（依通路）

  • 診所服務
    • 婦科綜合診所
    • 專科不孕症診所
  • 居家照護測試
  • 醫院服務
  • 獨立研究機構

12.美國女性不孕症診斷與治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

13. 歐洲、中東和非洲女性不孕症診斷與治療市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

14. 亞太女性不孕症診斷與治療市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第15章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Ferring BV
    • Thermo Fisher Scientific Inc.
    • Abbott Diagnostics
    • Bayer AG
    • Cook Group Incorporated
    • CooperSurgical Inc.
    • F. Hoffmann-La Roche Ltd.
    • FUJIFILM Irvine Scientific, Inc. by FUJIFILM Holdings Corporation
    • Genea Pty Limited
    • GlaxoSmithKline PLC
    • Halotech DNA SL
    • Merck & Co., Inc.
    • Qiagen NV
    • Theramex by Kanga Health Ltd.

第16章 研究人工智慧

第17章 研究統計

第18章 研究聯絡人

第19章 研究報導

第20章 附錄

Product Code: MRR-FE70EC183B6E

The Female Infertility Diagnosis & Treatment Market was valued at USD 4.90 billion in 2024 and is projected to grow to USD 5.29 billion in 2025, with a CAGR of 8.14%, reaching USD 7.85 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 4.90 billion
Estimated Year [2025] USD 5.29 billion
Forecast Year [2030] USD 7.85 billion
CAGR (%) 8.14%

Emerging Dynamics in Female Infertility Diagnosis and Treatment Highlighting Critical Challenges and Opportunities for Stakeholders Across Healthcare Ecosystems

Female infertility diagnosis and treatment has emerged as a critical focal area within reproductive health, driven by evolving patient expectations and technological breakthroughs. Over the past decade, increasing awareness of infertility issues, coupled with demographic shifts toward delayed childbearing, has created unprecedented demand for sophisticated diagnostic tools and tailored treatment modalities. Consequently, healthcare providers and product developers are under pressure to refine clinical protocols and introduce innovative solutions that enhance success rates while minimizing patient burden.

Building on these dynamics, diagnostic blood panels and advanced imaging techniques are now complemented by genetic testing capabilities that offer deeper insights into underlying causes of infertility. In parallel, treatment paradigms have transcended conventional ovulation induction to integrate personalized regimens encompassing in vitro fertilization enhancements and cryopreservation refinements. These advances underscore the importance of coordinated care teams who can navigate complex treatment pathways and ensure comprehensive support from initial evaluation through to embryo transfer.

Moreover, regulatory agencies have begun to harmonize guidelines for assisted reproductive technologies, paving the way for broader adoption and insurance reimbursement frameworks. As a result, market participants must align their development pipelines with evolving compliance standards to mitigate risk while capturing emerging opportunities. In this landscape, stakeholders-from clinicians to laboratory specialists-must collaborate seamlessly to translate cutting-edge research into actionable care protocols that deliver tangible outcomes for patients.

Key Technological and Clinical Shifts Redefining the Landscape of Female Infertility Diagnosis and Treatment for Enhanced Patient Outcomes and Care Pathways

Rapid innovations in diagnostic and therapeutic technologies have fundamentally altered the female infertility landscape, creating a wave of transformative shifts that promise improved efficacy and patient experience. Novel biomarker panels and next-generation sequencing have elevated the precision of genetic testing, enabling practitioners to identify chromosomal abnormalities and hereditary risk factors with greater confidence. This genetic insight is now informing targeted treatment plans that optimize stimulation protocols and embryo selection criteria.

Simultaneously, the integration of artificial intelligence into ultrasound imaging and decision-support systems has streamlined clinical workflows, reducing time to diagnosis and enhancing predictive accuracy for treatment outcomes. Meanwhile, refinements in cryopreservation techniques-such as vitrification-have significantly improved post-thaw survival rates of oocytes and embryos, offering greater flexibility in cycle scheduling and enabling fertility preservation initiatives for oncological and elective cases alike.

Telehealth platforms have also emerged as critical enablers, allowing remote monitoring of hormone levels and follicular development. This shift toward hybrid care models not only increases patient convenience but also optimizes resource utilization in fertility clinics. Moreover, the growing emphasis on personalized medicine is driving pharmaceutical research toward novel fertility medications that act on specific receptor pathways, reducing adverse effects while enhancing ovarian response. These interrelated developments collectively mark a pivotal evolution in the way infertility is diagnosed, managed, and treated.

Assessing the Widespread Effects of United States Tariff Adjustments on the Supply Chain and Cost Structures in Female Infertility Diagnosis and Treatment

In early 2025, the implementation of new United States tariffs on imported medical devices, laboratory reagents, and pharmaceutical compounds has introduced fresh challenges to the supply chain underpinning female infertility services. Equipment manufacturers have experienced higher input costs for ultrasound probes and incubators, while diagnostic reagent suppliers face elevated duties on genetic testing kits. As a result, clinics and laboratories must reassess procurement strategies to maintain price stability for patients.

Beyond cost considerations, the tariffs have spurred manufacturers to explore alternative sourcing options, including regional production hubs in North America and trade agreements with non-tariffed partners. Although these adaptations require upfront investment, they are expected to mitigate long-term exposure to volatile trade policies. In the short term, however, some smaller independent laboratories may experience budgetary strain, leading to potential consolidation within the market as larger service providers absorb or partner with struggling units.

Additionally, pharmaceutical companies that rely on imported active pharmaceutical ingredients for fertility medications have encountered supply delays, which in turn affect treatment scheduling and patient satisfaction. In response, several stakeholders are negotiating direct supply contracts and investing in domestic API production capacities. This cumulative impact of tariff adjustments highlights the need for agile supply chain management and underscores the importance of diversifying sourcing strategies to preserve continuity of care in female infertility diagnosis and treatment.

Deep Dive into Treatment Methods Diagnosis Techniques Infertility Types and Distribution Channels Revealing Nuanced Market Segmentation Dynamics

A nuanced understanding of market segmentation reveals critical avenues for growth and differentiation in female infertility services. Treatment methods can be categorized across assisted reproductive technology, cryopreservation, fertility medications, and surgical intervention, with assisted reproductive technology encompassing techniques such as gamete intrafallopian transfer, in vitro fertilization, intracytoplasmic sperm injection, and intrauterine insemination. Within cryopreservation, advances in embryo, oocyte, and sperm preservation are driving patient demand for fertility preservation options. Fertility medications range from clomiphene citrate to gonadotropins and letrozole, each offering distinct risk-benefit profiles. Surgical interventions include hysteroscopic and laparoscopic surgeries, myomectomy, and tubal surgery, each tailored to specific anatomical or pathological conditions.

Diagnosis techniques further refine service offerings through blood diagnostics, genetic testing, hysterosalpingography, laparoscopy, and ultrasound imaging. Blood diagnostics panels include anti-Mullerian hormone, follicle stimulating hormone, luteinizing hormone, and prolactin assays, enabling clinicians to personalize treatment protocols based on ovarian reserve and endocrine function. Type of infertility segmentation differentiates between primary and secondary infertility, highlighting distinct patient journeys and clinical considerations. Distribution channels cover clinic services, home care testing, hospital services, and independent laboratories, with clinic services divided into general gynecology clinics and specialized fertility centers. Together, these segmentation insights inform strategic decisions on service design, resource allocation, and targeted patient engagement across the continuum of care.

Evaluating Regional Variations Across Americas Europe Middle East Africa and Asia Pacific in Female Infertility Diagnosis and Treatment Trends

Regional dynamics play a pivotal role in shaping access, reimbursement, and adoption rates for female infertility diagnosis and treatment modalities. In the Americas, expansive private healthcare networks and growing insurance coverage for assisted reproductive technology have fueled clinic expansions and increased patient throughput. Regulatory frameworks in North America continue to evolve, with some states granting greater autonomy in reproductive tourism and cross-border care, while Latin American markets leverage cost-effective service models to attract international patients.

Within Europe, Middle East & Africa, diverse healthcare infrastructures and reimbursement policies create a fragmented landscape. Western European nations benefit from comprehensive insurance schemes and well-established fertility networks, whereas in emerging markets in the Middle East and North Africa, government-backed initiatives are accelerating the construction of specialty clinics. Compliance requirements differ significantly across jurisdictions, requiring product developers and service providers to tailor market entry strategies accordingly.

Asia-Pacific has emerged as a high-growth region, driven by demographic trends toward delayed parenthood in urban centers. Nations such as Japan and South Korea lead in technological adoption, while India and Southeast Asian countries compete on affordability and service volume, attracting patients from neighboring regions. Government incentives for domestic manufacturing and telehealth expansions further amplify the region's potential. As a result, stakeholders must develop multi-regional playbooks that account for the unique regulatory, cultural, and economic factors influencing demand for fertility services across these diverse markets.

Profiling Leading Industry Players and Their Strategic Initiatives Driving Innovation in Female Infertility Diagnosis and Treatment Solutions

Leading players in the female infertility space are leveraging a mix of strategic partnerships, R&D investments, and geographic expansion to strengthen their market position. Diagnostic innovators are pursuing collaborations with academic institutions to validate biomarker discovery, while equipment manufacturers are entering joint ventures to co-develop integrated IVF lab consoles. Pharmaceutical companies are bolstering late-stage clinical pipelines for next-generation fertility drugs, aiming to reduce cycle cancellation rates and minimize side effects associated with ovarian stimulation.

Notably, several laboratory service providers have adopted digital platforms that harmonize patient data from disparate testing modalities, offering seamless clinician access and automated reporting. Some firms are also acquiring smaller boutique labs to broaden their test menus and consolidate technical expertise under a unified quality management system. Companies in cryopreservation have introduced proprietary vitrification solutions, emphasizing post-thaw viability and ease of use for embryologists.

Concurrent with these innovations, market leaders are expanding into underserved regions through greenfield clinic openings and franchise models. They are also establishing patient support programs that encompass financial counseling, psychological services, and telemedicine follow-ups, enhancing patient adherence and satisfaction. Collectively, these strategic moves illustrate how companies are shaping the competitive landscape and accelerating the translation of novel technologies into routine clinical practice.

Strategic Imperatives and Practical Steps for Industry Leaders to Enhance Competitiveness and Foster Sustainable Growth in Female Infertility Care

Industry leaders seeking to maintain a competitive edge must adopt a multi-pronged strategy that balances technological innovation with patient-centric care models. First, aligning internal R&D priorities with emerging clinical needs-such as non-invasive embryo diagnostics and single-cell genetic assays-can unlock new value propositions. Simultaneously, investing in modular clinic architectures and digital health platforms will enable scalable service delivery across diverse geographies.

Next, fostering cross-sector partnerships with supply chain specialists and telehealth providers can optimize cost structures and extend remote monitoring capabilities. By integrating real-time data analytics into patient management systems, organizations can predict treatment responses and proactively adjust protocols to improve outcomes. Additionally, standardizing quality metrics and publishing outcome data will enhance transparency and build trust among prospective patients and payers.

Finally, embracing agile regulatory pathways and engaging with health authorities early in the development cycle can expedite product approvals and reimbursement alignment. Establishing centers of excellence for training clinicians and laboratory personnel will ensure consistent protocol adherence, while patient education initiatives can demystify treatment options and improve engagement. These actionable steps, taken in concert, will position industry leaders to deliver superior clinical efficacy, operational efficiency, and patient satisfaction.

In-Depth Explanation of the Research Framework Data Sources and Analytical Approaches Underpinning the Study on Female Infertility Care Innovations

This study employed a comprehensive research framework combining primary interviews, secondary data triangulation, and expert validation to ensure robust and actionable insights. Primary research involved structured discussions with fertility specialists, laboratory directors, and supply chain managers to capture firsthand perspectives on technology adoption and operational challenges. Secondary sources included peer-reviewed journals, regulatory filings, and clinical trial registries to contextualize emerging trends against established evidence.

Quantitative analysis leveraged anonymized case series from leading clinics, while qualitative synthesis distilled strategic narratives from stakeholder interviews. Data sources were meticulously cross-referenced to identify convergent themes and outliers, thereby enhancing the reliability of key findings. The team applied scenario planning techniques to assess the potential impact of policy changes, such as tariff adjustments and regulatory updates, on market dynamics.

Expert validation panels provided iterative feedback on draft frameworks, ensuring that segmentation schemas and regional insights accurately reflected real-world conditions. Ethical guidelines and data privacy standards were rigorously maintained throughout the research process. This mixed-methodology approach underpins the credibility of the study, offering decision-makers a transparent pathway from raw data to strategic recommendations.

Summarizing Pivotal Findings and the Strategic Outlook Poised to Shape the Future of Female Infertility Diagnosis and Therapeutic Interventions

This executive summary has illuminated key drivers, emerging technologies, and strategic considerations shaping female infertility diagnosis and treatment. From advanced genetic testing methodologies and AI-enabled imaging platforms to the operational ramifications of new tariff policies, the landscape is in a state of rapid evolution. Segmentations across treatment methods, diagnostic techniques, infertility types, and distribution channels provide a multidimensional view of market complexities and patient needs.

Regional analyses underscore the importance of tailored strategies, as dynamic regulatory environments and economic factors influence adoption rates in the Americas, Europe, Middle East & Africa, and Asia-Pacific. Case studies of leading companies reveal how strategic collaborations, targeted R&D, and patient support initiatives are redefining competitive advantages. Actionable recommendations emphasize the integration of digital health, quality standardization, and agile regulatory engagement to drive sustainable growth.

Looking ahead, the confluence of personalized medicine and data-driven decision support will continue to unlock higher success rates and optimize resource utilization. Stakeholders who proactively adapt to these trends-while maintaining a steadfast commitment to patient-centered care-will be best positioned to lead the next wave of innovation in female infertility treatment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Integration of artificial intelligence algorithms in personalized infertility treatment planning
  • 5.2. Growing adoption of telehealth platforms for virtual fertility consultations and remote monitoring
  • 5.3. Expansion of at home hormone monitoring solutions for early detection of ovulatory disorders
  • 5.4. Advances in non invasive endometrial receptivity assays improving embryo transfer success rates
  • 5.5. Increased use of microfluidic sperm sorting technologies to improve fertilization success in ivf cycles
  • 5.6. Integration of gut microbiome profiling in fertility assessments to personalize treatment decisions
  • 5.7. Regulatory shifts favoring expansion of over the counter fertility diagnostic kits and services
  • 5.8. Emergence of personalized ovarian tissue cryopreservation protocols enhancing fertility preservation outcomes
  • 5.9. Growing emphasis on patient centered digital support tools to reduce emotional stress during infertility treatment
  • 5.10. Patient-centered digital support platforms provide emotional care tools and community engagement during infertility treatments

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Female Infertility Diagnosis & Treatment Market, by Treatment Method

  • 8.1. Introduction
  • 8.2. Assisted Reproductive Technology
    • 8.2.1. Gamete Intrafallopian Transfer
    • 8.2.2. In Vitro Fertilization
    • 8.2.3. Intracytoplasmic Sperm Injection
    • 8.2.4. Intrauterine Insemination
  • 8.3. Cryopreservation
    • 8.3.1. Embryo Cryopreservation
    • 8.3.2. Oocyte Cryopreservation
    • 8.3.3. Sperm Cryopreservation
  • 8.4. Fertility Medications
    • 8.4.1. Clomiphene Citrate
    • 8.4.2. Gonadotropins
    • 8.4.3. Letrozole
  • 8.5. Surgical Intervention
    • 8.5.1. Hysteroscopic Surgery
    • 8.5.2. Laparoscopic Surgery
    • 8.5.3. Myomectomy
    • 8.5.4. Tubal Surgery

9. Female Infertility Diagnosis & Treatment Market, by Diagnosis Technique

  • 9.1. Introduction
  • 9.2. Blood Diagnostics
    • 9.2.1. Anti Mullerian Hormone Test
    • 9.2.2. Follicle Stimulating Hormone Test
    • 9.2.3. Luteinizing Hormone Test
    • 9.2.4. Prolactin Test
  • 9.3. Genetic Testing
  • 9.4. Hysterosalpingography
  • 9.5. Laparoscopy
  • 9.6. Ultrasound Imaging

10. Female Infertility Diagnosis & Treatment Market, by Type of Infertility

  • 10.1. Introduction
  • 10.2. Primary Infertility
  • 10.3. Secondary Infertility

11. Female Infertility Diagnosis & Treatment Market, by Distribution Channel

  • 11.1. Introduction
  • 11.2. Clinic Services
    • 11.2.1. General Gynecology Clinics
    • 11.2.2. Specialized Fertility Clinics
  • 11.3. Home Care Testing
  • 11.4. Hospital Services
  • 11.5. Independent Laboratories

12. Americas Female Infertility Diagnosis & Treatment Market

  • 12.1. Introduction
  • 12.2. United States
  • 12.3. Canada
  • 12.4. Mexico
  • 12.5. Brazil
  • 12.6. Argentina

13. Europe, Middle East & Africa Female Infertility Diagnosis & Treatment Market

  • 13.1. Introduction
  • 13.2. United Kingdom
  • 13.3. Germany
  • 13.4. France
  • 13.5. Russia
  • 13.6. Italy
  • 13.7. Spain
  • 13.8. United Arab Emirates
  • 13.9. Saudi Arabia
  • 13.10. South Africa
  • 13.11. Denmark
  • 13.12. Netherlands
  • 13.13. Qatar
  • 13.14. Finland
  • 13.15. Sweden
  • 13.16. Nigeria
  • 13.17. Egypt
  • 13.18. Turkey
  • 13.19. Israel
  • 13.20. Norway
  • 13.21. Poland
  • 13.22. Switzerland

14. Asia-Pacific Female Infertility Diagnosis & Treatment Market

  • 14.1. Introduction
  • 14.2. China
  • 14.3. India
  • 14.4. Japan
  • 14.5. Australia
  • 14.6. South Korea
  • 14.7. Indonesia
  • 14.8. Thailand
  • 14.9. Philippines
  • 14.10. Malaysia
  • 14.11. Singapore
  • 14.12. Vietnam
  • 14.13. Taiwan

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Ferring B.V.
    • 15.3.2. Thermo Fisher Scientific Inc.
    • 15.3.3. Abbott Diagnostics
    • 15.3.4. Bayer AG
    • 15.3.5. Cook Group Incorporated
    • 15.3.6. CooperSurgical Inc.
    • 15.3.7. F. Hoffmann-La Roche Ltd.
    • 15.3.8. FUJIFILM Irvine Scientific, Inc. by FUJIFILM Holdings Corporation
    • 15.3.9. Genea Pty Limited
    • 15.3.10. GlaxoSmithKline PLC
    • 15.3.11. Halotech DNA S.L.
    • 15.3.12. Merck & Co., Inc.
    • 15.3.13. Qiagen N.V.
    • 15.3.14. Theramex by Kanga Health Ltd.

16. ResearchAI

17. ResearchStatistics

18. ResearchContacts

19. ResearchArticles

20. Appendix

LIST OF FIGURES

  • FIGURE 1. FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT METHOD, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT METHOD, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TYPE OF INFERTILITY, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TYPE OF INFERTILITY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 14. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 16. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 22. FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 23. FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET: RESEARCHAI
  • FIGURE 24. FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET: RESEARCHSTATISTICS
  • FIGURE 25. FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET: RESEARCHCONTACTS
  • FIGURE 26. FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT METHOD, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT METHOD, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY GAMETE INTRAFALLOPIAN TRANSFER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY GAMETE INTRAFALLOPIAN TRANSFER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY IN VITRO FERTILIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY IN VITRO FERTILIZATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY INTRACYTOPLASMIC SPERM INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY INTRACYTOPLASMIC SPERM INJECTION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY INTRAUTERINE INSEMINATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY INTRAUTERINE INSEMINATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CRYOPRESERVATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CRYOPRESERVATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY EMBRYO CRYOPRESERVATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY EMBRYO CRYOPRESERVATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY OOCYTE CRYOPRESERVATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY OOCYTE CRYOPRESERVATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SPERM CRYOPRESERVATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SPERM CRYOPRESERVATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CRYOPRESERVATION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CRYOPRESERVATION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FERTILITY MEDICATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FERTILITY MEDICATIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLOMIPHENE CITRATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLOMIPHENE CITRATE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY GONADOTROPINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY GONADOTROPINS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY LETROZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY LETROZOLE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FERTILITY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FERTILITY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY HYSTEROSCOPIC SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY HYSTEROSCOPIC SURGERY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY LAPAROSCOPIC SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY LAPAROSCOPIC SURGERY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MYOMECTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MYOMECTOMY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TUBAL SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TUBAL SURGERY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BLOOD DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BLOOD DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ANTI MULLERIAN HORMONE TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ANTI MULLERIAN HORMONE TEST, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FOLLICLE STIMULATING HORMONE TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FOLLICLE STIMULATING HORMONE TEST, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY LUTEINIZING HORMONE TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY LUTEINIZING HORMONE TEST, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PROLACTIN TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PROLACTIN TEST, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BLOOD DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BLOOD DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY GENETIC TESTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY HYSTEROSALPINGOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY HYSTEROSALPINGOGRAPHY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY LAPAROSCOPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY LAPAROSCOPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ULTRASOUND IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ULTRASOUND IMAGING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TYPE OF INFERTILITY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TYPE OF INFERTILITY, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRIMARY INFERTILITY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRIMARY INFERTILITY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SECONDARY INFERTILITY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SECONDARY INFERTILITY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLINIC SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLINIC SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY GENERAL GYNECOLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY GENERAL GYNECOLOGY CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SPECIALIZED FERTILITY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SPECIALIZED FERTILITY CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLINIC SERVICES, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLINIC SERVICES, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY HOME CARE TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY HOME CARE TESTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY HOSPITAL SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY HOSPITAL SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 97. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 99. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT METHOD, 2018-2024 (USD MILLION)
  • TABLE 100. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT METHOD, 2025-2030 (USD MILLION)
  • TABLE 101. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 102. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 103. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CRYOPRESERVATION, 2018-2024 (USD MILLION)
  • TABLE 104. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CRYOPRESERVATION, 2025-2030 (USD MILLION)
  • TABLE 105. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FERTILITY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 106. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FERTILITY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 107. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 108. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD MILLION)
  • TABLE 109. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 110. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2025-2030 (USD MILLION)
  • TABLE 111. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BLOOD DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 112. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BLOOD DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 113. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TYPE OF INFERTILITY, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TYPE OF INFERTILITY, 2025-2030 (USD MILLION)
  • TABLE 115. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 117. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLINIC SERVICES, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLINIC SERVICES, 2025-2030 (USD MILLION)
  • TABLE 119. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 121. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT METHOD, 2018-2024 (USD MILLION)
  • TABLE 122. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT METHOD, 2025-2030 (USD MILLION)
  • TABLE 123. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 124. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 125. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CRYOPRESERVATION, 2018-2024 (USD MILLION)
  • TABLE 126. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CRYOPRESERVATION, 2025-2030 (USD MILLION)
  • TABLE 127. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FERTILITY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 128. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FERTILITY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 129. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 130. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD MILLION)
  • TABLE 131. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 132. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2025-2030 (USD MILLION)
  • TABLE 133. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BLOOD DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 134. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BLOOD DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 135. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TYPE OF INFERTILITY, 2018-2024 (USD MILLION)
  • TABLE 136. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TYPE OF INFERTILITY, 2025-2030 (USD MILLION)
  • TABLE 137. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 138. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 139. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLINIC SERVICES, 2018-2024 (USD MILLION)
  • TABLE 140. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLINIC SERVICES, 2025-2030 (USD MILLION)
  • TABLE 141. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 142. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 143. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT METHOD, 2018-2024 (USD MILLION)
  • TABLE 144. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT METHOD, 2025-2030 (USD MILLION)
  • TABLE 145. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 146. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 147. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CRYOPRESERVATION, 2018-2024 (USD MILLION)
  • TABLE 148. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CRYOPRESERVATION, 2025-2030 (USD MILLION)
  • TABLE 149. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FERTILITY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 150. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FERTILITY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 151. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 152. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD MILLION)
  • TABLE 153. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 154. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2025-2030 (USD MILLION)
  • TABLE 155. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BLOOD DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 156. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BLOOD DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 157. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TYPE OF INFERTILITY, 2018-2024 (USD MILLION)
  • TABLE 158. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TYPE OF INFERTILITY, 2025-2030 (USD MILLION)
  • TABLE 159. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 160. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 161. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLINIC SERVICES, 2018-2024 (USD MILLION)
  • TABLE 162. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLINIC SERVICES, 2025-2030 (USD MILLION)
  • TABLE 163. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT METHOD, 2018-2024 (USD MILLION)
  • TABLE 164. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT METHOD, 2025-2030 (USD MILLION)
  • TABLE 165. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 166. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 167. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CRYOPRESERVATION, 2018-2024 (USD MILLION)
  • TABLE 168. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CRYOPRESERVATION, 2025-2030 (USD MILLION)
  • TABLE 169. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FERTILITY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 170. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FERTILITY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 171. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 172. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD MILLION)
  • TABLE 173. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 174. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2025-2030 (USD MILLION)
  • TABLE 175. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BLOOD DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 176. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BLOOD DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 177. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TYPE OF INFERTILITY, 2018-2024 (USD MILLION)
  • TABLE 178. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TYPE OF INFERTILITY, 2025-2030 (USD MILLION)
  • TABLE 179. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 180. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 181. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLINIC SERVICES, 2018-2024 (USD MILLION)
  • TABLE 182. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLINIC SERVICES, 2025-2030 (USD MILLION)
  • TABLE 183. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT METHOD, 2018-2024 (USD MILLION)
  • TABLE 184. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT METHOD, 2025-2030 (USD MILLION)
  • TABLE 185. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 186. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 187. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CRYOPRESERVATION, 2018-2024 (USD MILLION)
  • TABLE 188. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CRYOPRESERVATION, 2025-2030 (USD MILLION)
  • TABLE 189. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FERTILITY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 190. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FERTILITY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 191. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 192. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD MILLION)
  • TABLE 193. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 194. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2025-2030 (USD MILLION)
  • TABLE 195. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BLOOD DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 196. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BLOOD DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 197. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TYPE OF INFERTILITY, 2018-2024 (USD MILLION)
  • TABLE 198. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TYPE OF INFERTILITY, 2025-2030 (USD MILLION)
  • TABLE 199. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 200. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 201. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLINIC SERVICES, 2018-2024 (USD MILLION)
  • TABLE 202. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLINIC SERVICES, 2025-2030 (USD MILLION)
  • TABLE 203. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT METHOD, 2018-2024 (USD MILLION)
  • TABLE 204. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT METHOD, 2025-2030 (USD MILLION)
  • TABLE 205. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 206. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 207. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CRYOPRESERVATION, 2018-2024 (USD MILLION)
  • TABLE 208. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CRYOPRESERVATION, 2025-2030 (USD MILLION)
  • TABLE 209. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FERTILITY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 210. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FERTILITY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 211. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 212. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD MILLION)
  • TABLE 213. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 214. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2025-2030 (USD MILLION)
  • TABLE 215. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BLOOD DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 216. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BLOOD DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 217. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TYPE OF INFERTILITY, 2018-2024 (USD MILLION)
  • TABLE 218. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TYPE OF INFERTILITY, 2025-2030 (USD MILLION)
  • TABLE 219. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 220. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 221. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLINIC SERVICES, 2018-2024 (USD MILLION)
  • TABLE 222. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLINIC SERVICES, 2025-2030 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT METHOD, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT METHOD, 2025-2030 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CRYOPRESERVATION, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CRYOPRESERVATION, 2025-2030 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FERTILITY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FERTILITY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2025-2030 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BLOOD DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BLOOD DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TYPE OF INFERTILITY, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TYPE OF INFERTILITY, 2025-2030 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLINIC SERVICES, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLINIC SERVICES, 2025-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 245. UNITED KINGDOM FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT METHOD, 2018-2024 (USD MILLION)
  • TABLE 246. UNITED KINGDOM FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT METHOD, 2025-2030 (USD MILLION)
  • TABLE 247. UNITED KINGDOM FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 248. UNITED KINGDOM FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 249. UNITED KINGDOM FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CRYOPRESERVATION, 2018-2024 (USD MILLION)
  • TABLE 250. UNITED KINGDOM FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CRYOPRESERVATION, 2025-2030 (USD MILLION)
  • TABLE 251. UNITED KINGDOM FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FERTILITY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 252. UNITED KINGDOM FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FERTILITY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 253. UNITED KINGDOM FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 254. UNITED KINGDOM FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD MILLION)
  • TABLE 255. UNITED KINGDOM FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 256. UNITED KINGDOM FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2025-2030 (USD MILLION)
  • TABLE 257. UNITED KINGDOM FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BLOOD DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 258. UNITED KINGDOM FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BLOOD DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 259. UNITED KINGDOM FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TYPE OF INFERTILITY, 2018-2024 (USD MILLION)
  • TABLE 260. UNITED KINGDOM FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TYPE OF INFERTILITY, 2025-2030 (USD MILLION)
  • TABLE 261. UNITED KINGDOM FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DI